卵巢上皮性癌组织中细胞周期蛋白D1与p16的表达

目的 :探讨卵巢上皮性癌组织中细胞周期蛋白D1(CyclinD1)、p16的表达。方法 :应用SABC免疫组化技术 ,检测 40例卵巢上皮性癌、12例良性卵巢肿瘤和 10例正常卵巢组织中CyclinD1、p16的表达 ,并对二者表达与卵巢上皮性癌临床分期、组织学分级、组织学类型、有无淋巴结转移和生存时间之关系进行探讨。结果 :①CyclinD1阳性表达多见于临床期别晚、伴有淋巴结转移和生存期短的病例组 (P <0 0 5 ) ,低分化者阳性表达高于高分化者 ,Ⅲ级与Ⅱ级、Ⅰ级比较 ,差异有显著性 (P <0 0 5 )。②p16阳性表达多见于临床期别早、高分化、无淋巴结转移和生存期长的病例组 ,阴性多见于临床期别晚、低分化、伴有淋巴结转移和生存期短的病例组 (P <0 0 5 )。③p16表达与CyclinD1表达呈负相关。结论 :CyclinD1过表达和p16失表达与卵巢上皮性癌的临床病理指标有关 ,在其发病中有协同作用。

Expression of CyclinD1 and p16 in human ovarian epithelial cancer

Aim：To explore the role of expression of CyclinD1 and p16 in the progression of ovarian cancer.Methods： Immunohistochemical staining technique was used to examine the expression of CyclinD1 and p16 in 40 cases of ovarian epithelial cancers, 12 cases of benign ovarian tumors and 10 cases of normal ovaries. Both expressions were analyzed in terms of their relationships to clinical stages,differentiated grades,histological types,lymphatic node metastasis of the disease and the survival time of the patients.Results:①The higher expressions of CyclinD1 were found in groups at poorly clinical stage,with lymphatic node metastasis and short survival time than that of groups in well clinical stage,non-lymphatic node metastasis and long survival time (P＜0.05);It was higher in group of low differentiated grade than that of high differentiated grade.The expression was apparently different while grade Ⅲ was compared with grade Ⅱ or grade Ⅰ(P＜0.05).②The majority at well clinical stage orhigh differentiated grade,or with non-lymphatic node metastasis and long survival time were positive for p16 while it was negative in most of the poorly clinical stage,low differentiated grade,lymphatic node metastasis and short survival time (P＜0.05).③)There was negative correlation between the expression of p16 and the expression of CyclinD1.Conclusion： The low expression of p16 and the high expression of CyclinD1 are closely correlated to the clinicopathological parameters of ovarian cancer and have synergism effect in progression of ovaian epithelial cancer.